High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!
.
Chairman and Chief Executive Officer Image

Chairman and Chief Executive Officer

Paul M. Bisaro has served as President and Chief Executive Officer since September 2007.

  • Prior to joining Watson, Mr. Bisaro was President and Chief Operating Officer of Barr Pharmaceuticals, Inc. (“Barr”) from 1999 to 2007. Between 1992 and 1999, he served as General Counsel and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan in 1983 and a Juris Doctor from Catholic University of America in Washington, D.C. in 1989.

President, Actavis Pharma Image

President, Actavis Pharma

Siggi O. Olafsson was appointed President, Actavis Pharma on April 27, 2012.

  • Mr. Olafsson joined Watson as Executive Vice President, Global Generics in September 2010. Prior to joining Watson, he served as CEO of Actavis Group, where he was responsible for overseeing Actavis’ global pharmaceutical business with operations in more than 40 countries. From 2006 to 2008, Mr. Olafsson served as Deputy CEO of Actavis Group, and was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development from 2003-2006, where he led Actavis U.S. sales and marketing organization, and also led the acquisition and integration of Pharma Avalanche, Biovena, Lotus Laboratories, Amide Pharmaceuticals and Alpharma Generics. Prior to joining Actavis, Mr. Olafsson held increasingly responsible positions with Pfizer’s Global Research and Development organization in both the U.S. and in the U.K. from 1998 until 2003. Prior to joining Pfizer, he served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy (Cand Pharm) from the University of Iceland.

President, Actavis Global R&D Image

President, Actavis Global R&D

Fred Wilkinson was appointed President, Global R&D on January 31, 2014.

  • Mr. Wilkinson joined Watson as Executive Vice President, Global Brands in September 2009. Prior to joining Watson, he was President and Chief Operating Officer of Duramed Pharmaceuticals, Inc. the proprietary products subsidiary of Barr from 2006 to 2009. Prior to joining Duramed Pharmaceuticals, Inc., he was President and Chief Executive Officer of Columbia Laboratories, Inc. from 2001 to 2006. From 1996 to 2001, Mr. Wilkinson was Senior Vice President and Chief Operating Officer of Watson Pharmaceuticals, Inc. Prior to joining Watson, he spent 16 years at Sandoz in numerous senior management positions of increasing responsibility. Mr. Wilkinson received his M.B.A. from Capital University in 1984 and his B.S. in Pharmacy from Ohio Northern University in 1979.

President, Global Operations Image

President, Global Operations

Bob Stewart was appointed President, Global Operations on April 27, 2012.

  • As President, Global Operations, Mr. Stewart is responsible for managing the Company’s Anda, Inc. distribution business, in addition to Global Operations. He had served as Executive Vice President, Global Operations, since August 2010. He joined Watson in November 2009 as Senior Vice President, Global Operations. Prior to joining Watson, Mr. Stewart held various positions with Abbott Laboratories, Inc. from 2002 until 2009 where he most recently served as Vice President, Global Supply Chain. From 2005 until 2008, he served as Divisional Vice President, Quality Assurance and prior to this position served as Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations as well as Director of Operations for Abbott’s Whippany plant. Prior to joining Abbott Laboratories, Inc., he worked for Knoll Pharmaceutical Company from 1995 to 2001 and Hoffman La-Roche Inc. Mr. Stewart received B.S. degrees in Business Management/Finance in 1994 from Fairleigh Dickinson University.

Chief Financial Officer – Global Image

Chief Financial Officer – Global

Todd Joyce was appointed Chief Financial Officer – Global on April 27, 2012.

  • Mr. Joyce had served as Executive Vice President, Chief Financial Officer since March 2011. He had previously served as Senior Vice President, Chief Financial Officer since October 2009. He joined Watson in 1997 as Corporate Controller, and was named Vice President, Corporate Controller and Treasurer in 2001. During the periods October 2006 to November 2007 and from July 2009 until his appointment as Chief Financial Officer, Mr. Joyce served as interim Principal Financial Officer. Prior to joining Watson, Mr. Joyce served as Vice President of Tax from 1992 to 1996 and as Vice President of Tax and Finance from 1996 until 1997 at ICN Pharmaceuticals. Prior to ICN Pharmaceuticals, Mr. Joyce served as a Certified Public Accountant with Coopers & Lybrand and Price Waterhouse. Mr. Joyce received a B.S. in Business Administration from the University of North Carolina at Chapel Hill in 1983 and a M.S. in Taxation from Golden Gate University in 1992.

Chief Legal Officer - Global Image

Chief Legal Officer - Global

David A. Buchen was appointed Chief Legal Officer - Global on April 27, 2012. He also serves as Secretary to the Board of Directors.

  • Mr. Buchen had served as Executive Vice President, General Counsel and Secretary since March 2011. He had previously served as Senior Vice President, General Counsel and Secretary since November 2002. From November 2000 to November 2002, Mr. Buchen served as Vice President and Associate General Counsel. From February 2000 to November 2000, he served as Vice President and Senior Corporate Counsel. From November 1998 to February 2000, he served as Senior Corporate Counsel and as Corporate Counsel. He also served as Assistant Secretary from February 1999 to November 2002. Prior to joining Watson, Mr. Buchen was Corporate Counsel at Bausch & Lomb Surgical (formerly Chiron Vision Corporation) from November 1995 until November 1998 and was an attorney with the law firm of Fulbright & Jaworski, LLP. Mr. Buchen received a B.A. in Philosophy from the University of California, Berkeley in 1985, and a Juris Doctor with honors from George Washington University Law School in 1989.

Chief Human Resources Officer – Global Image

Chief Human Resources Officer – Global

Patrick Eagan was appointed Chief Human Resources Officer – Global on November 1, 2012, after having served as Senior Vice President, Human Resources – Global since April 2012.

  • Mr. Eagan joined Watson in 2011 as Senior Vice President, Human Resources. Prior to Watson, he served nearly 20 years with Abbott Laboratories, holding numerous positions of increasing responsibility. Prior to joining Watson, Mr. Eagan was Divisional Vice President, Human Resources, Global Pharmaceuticals Operations for Abbott. He was promoted to this position in 2009, having served as Divisional Vice President, Human Resources, Pharmaceutical Products U.S. since 2007. He joined Abbott in 1993, and held a number of increasingly responsible positions in various Abbott business segments. Prior to joining Abbott in 1993, Mr. Eagan held a number of human resources positions with McDonnell Douglas Corporation. He has a B.S. in Business Administration from the University of Missouri; an MBA from Lindenwood College; and has attended Executive HR Development programs at the University of Michigan.

Chief Communications Officer – Global Image

Chief Communications Officer – Global

Charlie Mayr was appointed Chief Communications Officer on April 27, 2012.

  • Mr. Mayr joined Watson as Senior Vice President, Corporate Affairs in September 2009. Prior to joining Watson, Mr. Mayr operated an advertising and public relations consulting company from 1998 to 2009, serving such clients as Watson, the Generic Pharmaceutical Association (GPhA), Barr Pharmaceuticals and a variety of professional associations and consumer products and service companies. Prior to starting his consultancy business, he served as Director of Corporate Communications for Barr Pharmaceuticals, Inc. from 1994 to 1998. Prior to joining Barr, he served as Director of Global Communications from 1990 to 1994 for Sterling Drug Inc., the global brand and consumer health products pharmaceutical subsidiary of Kodak. Mr. Mayr began his career as a broadcast and print journalist and has a B.A. in journalism from New York University.